RPS19 and hepatocellular carcinoma: This is in agreement with the study showing an increased binding of DBA lectin to hepatocellular carcinoma cells treated with the multikinase inhibitor sorafenib, while the binding of lectins such as MAA, PHAL, RCA and SNA was significantly reduced for the cells treated with sorafenib on a lectin microarray using a cytosolic cell fraction.44